What are insulin price caps, and who do they actually apply to?
The Arguments
WHAT THE INDUSTRY ARGUES
Supporters of insulin price caps argue that the rising cost of insulin places an unsustainable financial burden on millions of Americans with diabetes, forcing some to ration a lifesaving drug. The bipartisan INSULIN Act would cap out-of-pocket insulin costs at $35 per month. According to Fox News reporting, the bill aims to cover both insured and uninsured Americans starting in 2027, broadening protections beyond current law, which primarily benefits Medicare enrollees through a $35 cap enacted in 2022.
WHAT CRITICS ARGUE
Critics and skeptics note that previous legislative efforts to cap insulin costs for privately insured and uninsured Americans have repeatedly stalled in Congress, suggesting political and industry obstacles remain significant. Some question whether a price cap at the point of sale truly addresses the underlying pricing structures set by manufacturers and pharmacy benefit managers, potentially shifting costs elsewhere in the healthcare system rather than reducing them overall.
The Data
WHAT THE DATA SHOWS
The bipartisan INSULIN Act of 2026 would cap insulin costs at $35 per month. According to PBS, the bill specifically targets Americans with private insurance plans, while Fox News reports the legislation also aims to include uninsured Americans, with an intended start date of 2027. Currently, a $35 monthly insulin cap exists only for Medicare Part D enrollees. No CMS data was available to quantify the broader population impact.
The Bottom Line
BOTTOM LINE
The proposed INSULIN Act seeks to extend a $35 monthly insulin price cap beyond Medicare to privately insured and potentially uninsured Americans, but the bill has not yet been enacted into law.